XML 53 R36.htm IDEA: XBRL DOCUMENT
v3.25.2

Segment Information (Tables) | 12 Months Ended
--- | ---
Jun. 30, 2025
Notes Tables |
Schedule of financial information by reportable segment | The following is financial information relating to the operating segments (in thousands):
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
For the Year Ended June 30, 2025
​ | ​ | Protein Sciences | ​ | ​ | Diagnostics and Spatial Biology | ​ | ​ | Total
Net sales | $ | 870,245 | ​ | $ | 346,263 | ​ | $ | 1,216,508
Other revenue(1) | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 4,152
Intersegment | ​ | ​ | ​ | ​ | ​ | ​ | ​ | (1,025)
Consolidated net sales | ​ | ​ | ​ | ​ | ​ | ​ | $ | 1,219,635
Segment operating income | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Cost of sales | ​ | 212,225 | ​ | ​ | 147,946 | ​ | ​ | ​
Selling, general and administrative | ​ | 229,058 | ​ | ​ | 136,103 | ​ | ​ | ​
Research and development | ​ | 58,609 | ​ | ​ | 40,890 | ​ | ​ | ​
Segment operating income | $ | 370,353 | ​ | $ | 21,324 | ​ | $ | 391,677
Unallocated amounts | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Costs recognized on sale of acquired inventory | ​ | ​ | ​ | ​ | ​ | ​ | ​ | (751)
Amortization of intangibles | ​ | ​ | ​ | ​ | ​ | ​ | ​ | (75,321)
Acquisition related expenses and other | ​ | ​ | ​ | ​ | ​ | ​ | ​ | (12,064)
Certain litigation charges | ​ | ​ | ​ | ​ | ​ | ​ | ​ | (41,827)
Impairment of assets held-for-sale | ​ | ​ | ​ | ​ | ​ | ​ | ​ | (80,503)
Stock based compensation, inclusive of employer taxes | ​ | ​ | ​ | ​ | ​ | ​ | ​ | (42,158)
Restructuring and restructuring-related costs | ​ | ​ | ​ | ​ | ​ | ​ | ​ | (28,231)
Corporate general, selling, and administrative expenses | ​ | ​ | ​ | ​ | ​ | ​ | ​ | (8,088)
Impact of business held-for-sale(1) | ​ | ​ | ​ | ​ | ​ | ​ | ​ | (479)
Consolidated operating income | ​ | ​ | ​ | ​ | ​ | ​ | $ | 102,255
​
(1) | Since December 31, 2023, the Company has a business that has met the held-for-sale criteria. Segment results exclude the results of this business held-for-sale for fiscal 2025.
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
For the Year Ended June 30, 2024
​ | ​ | Protein Sciences | ​ | ​ | Diagnostics and Spatial Biology | ​ | ​ | Total
Net sales | $ | 830,902 | ​ | $ | 326,392 | ​ | $ | 1,157,294
Other revenue(1) | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 4,153
Intersegment | ​ | ​ | ​ | ​ | ​ | ​ | ​ | (2,387)
Consolidated net sales | ​ | ​ | ​ | ​ | ​ | ​ | $ | 1,159,060
Segment operating income | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Cost of sales | ​ | 201,981 | ​ | ​ | 134,963 | ​ | ​ | ​
Selling, general and administrative | ​ | 217,235 | ​ | ​ | 127,131 | ​ | ​ | ​
Research and development | ​ | 56,911 | ​ | ​ | 39,752 | ​ | ​ | ​
Segment operating income | $ | 354,775 | ​ | $ | 24,546 | ​ | $ | 379,321
Unallocated amounts | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Costs recognized on sale of acquired inventory | ​ | ​ | ​ | ​ | ​ | ​ | ​ | (729)
Amortization of intangibles | ​ | ​ | ​ | ​ | ​ | ​ | ​ | (78,318)
Acquisition related expenses and other | ​ | ​ | ​ | ​ | ​ | ​ | ​ | (6,980)
Certain litigation charges | ​ | ​ | ​ | ​ | ​ | ​ | ​ | (3,506)
Impairment of assets held-for-sale | ​ | ​ | ​ | ​ | ​ | ​ | ​ | (21,963)
Stock based compensation, inclusive of employer taxes | ​ | ​ | ​ | ​ | ​ | ​ | ​ | (40,277)
Restructuring and restructuring-related costs | ​ | ​ | ​ | ​ | ​ | ​ | ​ | (12,245)
Corporate general, selling, and administrative expenses | ​ | ​ | ​ | ​ | ​ | ​ | ​ | (9,142)
Impact of business held-for-sale(1) | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 525
Consolidated operating income | ​ | ​ | ​ | ​ | ​ | ​ | $ | 206,686
​
(1) | Since December 31, 2023, the Company has a business that has met the held-for-sale criteria. Segment results exclude the six-month results of this business held-for-sale for the period starting December 31, 2023 through June 30, 2024 while the business has met the held-for-sale criteria.
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
For the Year Ended June 30, 2023
​ | ​ | Protein Sciences | ​ | ​ | Diagnostics and Spatial Biology | ​ | ​ | Total
Net sales | $ | 845,747 | ​ | $ | 292,602 | ​ | $ | 1,138,349
Intersegment | ​ | ​ | ​ | ​ | ​ | ​ | ​ | (1,647)
Consolidated net sales | ​ | ​ | ​ | ​ | ​ | ​ | $ | 1,136,702
Segment operating income | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Cost of sales | ​ | 209,332 | ​ | ​ | 113,517 | ​ | ​ | ​
Selling, general and administrative | ​ | 204,480 | ​ | ​ | 101,806 | ​ | ​ | ​
Research and development | ​ | 58,251 | ​ | ​ | 34,242 | ​ | ​ | ​
Segment operating income | $ | 373,684 | ​ | $ | 43,037 | ​ | $ | 416,721
Unallocated amounts | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Costs recognized on sale of acquired inventory | ​ | ​ | ​ | ​ | ​ | ​ | ​ | (400)
Amortization of intangibles | ​ | ​ | ​ | ​ | ​ | ​ | ​ | (76,413)
Impact of partially-owned consolidated subsidiaries | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 647
Acquisition related expenses and other | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 9,965
Stock based compensation, inclusive of employer taxes | ​ | ​ | ​ | ​ | ​ | ​ | ​ | (41,217)
Restructuring and restructuring-related costs | ​ | ​ | ​ | ​ | ​ | ​ | ​ | (3,829)
Corporate general, selling, and administrative expenses | ​ | ​ | ​ | ​ | ​ | ​ | ​ | (6,530)
Consolidated operating income | ​ | ​ | ​ | ​ | ​ | ​ | $ | 298,944
​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Year Ended June 30,
​ |  | 2025 |  | 2024 |  | 2023
Consumables revenue - Protein Sciences | ​ | $ | 684,165 | ​ | $ | 657,679 | ​ | $ | 665,301
Consumables revenue - Diagnostics and Spatial Biology | ​ |  | 283,969 | ​ |  | 266,348 | ​ |  | 252,432
Consumables revenue - Other revenue(1) | ​ | ​ | 4,152 | ​ | ​ | 4,153 | ​ | ​ | —
Total consumable revenue | ​ | $ | 972,286 | ​ | $ | 928,180 | ​ | $ | 917,733
(1) | Includes the results of a business that has met the held-for-sale criteria since December 31, 2023.
Schedule of financial information relating to geographic areas | ​
​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Year ended June 30,
​ |  | 2025 |  | 2024
Long-lived assets: | ​ | ​ | ​ | ​ | ​ | ​
United States and Canada | ​ | $ | 202,800 |  | $ | 211,597
Europe |  |  | 36,030 | ​ |  | 27,862
Asia | ​ |  | 6,889 | ​ |  | 11,695
Total long-lived assets | ​ | $ | 245,719 |  | $ | 251,154
Intangible assets: | ​ |  |  | ​ |  |
United States and Canada | ​ | $ | 301,971 |  | $ | 443,740
Europe | ​ |  | 63,628 | ​ |  | 63,138
Asia | ​ |  | — | ​ |  | 203
Total intangible assets | ​ | $ | 365,599 |  | $ | 507,081

X
- Definition Tabular disclosure of long-lived assets, excluding financial instruments, long-term customer relationships of a financial institution, mortgage rights, deferred policy acquisition costs, and deferred tax assets, by geographic areas located in the entity's country of domicile and foreign countries in which the entity holds assets. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 + Details
Name: | us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_TableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration